About
Delivery by Pseudo-Viruses
Areas of Focus
Categories
Virus TechnologyDrug Delivery & FormulationBoston & New England
Clinical Trials (8)
View allTotal Trials
8
As Lead Sponsor
8
As Collaborator
0
Total Enrollment
870
By Phase
PHASE1/PHASE2: 2PHASE2: 2PHASE3: 1PHASE1: 1
By Status
RECRUITING: 5COMPLETED: 2TERMINATED: 1
Clinical Trials Pipeline8 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT07148128Lead Sponsor
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
PHASE1/PHASE2Recruiting
110 participants
Started: Jul 28, 2025 · Completed: Jan 31, 2028
NCT06643884Lead Sponsor
Suprachoroidal Administration in Subjects With Metastases to the Choroid
PHASE2Recruiting
24 participants
Started: Dec 16, 2024 · Completed: Feb 28, 2027
NCT06007690Lead Sponsor
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
PHASE3Recruiting
100 participants
Started: Dec 6, 2023 · Completed: Mar 1, 2027
NCT05483868Lead Sponsor
A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
PHASE1Recruiting
55 participants
Started: Sep 26, 2022 · Completed: Apr 30, 2027
NCT05266430Lead Sponsor
Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)
N/ATerminated
2 participants
Started: Apr 14, 2022 · Completed: Apr 20, 2023
Locations (1)
Headquarters
Boston, MA, United States
Map
Loading map...